Trials / Completed
CompletedNCT03597516
Evaluation of the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Durability, Safety, and Tolerability of RP-G28 in Patients With Lactose Intolerance
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 557 (actual)
- Sponsor
- Ritter Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study conducted in the United States (US) to assess the efficacy of RP-G28 compared to placebo on symptom reduction related to lactose intolerance.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RP-G28 | powder for reconstitution for oral administration |
| DRUG | Placebos | powder for reconstitution for oral administration |
Timeline
- Start date
- 2018-06-26
- Primary completion
- 2019-07-02
- Completion
- 2019-07-02
- First posted
- 2018-07-24
- Last updated
- 2019-07-08
Locations
35 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03597516. Inclusion in this directory is not an endorsement.